LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 11, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company has been added to the NASDAQ Biotechnology Index (NBI). The addition is part of NBI's annual review of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on Monday, December 18, 2017.
The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market, that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December. Additional information on the eligibility criteria and further details about the index are available through this link.
About uniQure
uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
[email protected]
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
[email protected]
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
[email protected]


Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Washington Post Publisher Will Lewis Steps Down After Layoffs
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Anta Sports Expands Global Footprint With Strategic Puma Stake
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



